About Collatamp G
For over 20 years, surgeons throughout the world have been using Collatamp G to reduce the risk of and treat surgical site infections.
Collatamp G is a lyophilized collagen impact impregnated with the aminoglycoside antibiotic gentamicin that reduces the rate of surgical site infections more than 50%.3 By using Collatamp G to prevent and treat surgical site infections, your patients':
- Recovery time will be easier
- Need for repeat surgery will be reduced
- Need for readmission to hospital will decrease
- Risk of dying will lower
Collatamp G has been used in over 2 million patients for over 20 years globally, and there have been no reported side effects to date.
How does Collatamp G work?
Collatamp G is a localized drug-delivery system that is based on type-1 collagen matrix derived from bovine achilles tendon. The collagen impact is saturated with gentamicin, a powerful broad-spectrum antibiotic.
Collatamp G is a strong, effective adjunct to the lower dose prophylactic antibiotic protocols that are already used at your hospital. By delivering a high localized dose of gentamicin directly to the surgical site, Collatamp G kills bacteria that may be antibiotic-resistant at lower doses. It maintains a high concentration of drugs at the target site, while avoiding the risk of systemic toxicity and associated side effects.4
Advantages of a Collagen-Based Drug Delivery System
Many device-drug combination products—pumps for continuous infusion of local anesthetics, medicated stents and bone cements carrying an antibiotic—work well as localized delivery systems. Collagen, however, has the advantage of being a natural and well-established biocompatible material with proven wound-healing and hemostatic properties. The collagen matrix of Collatamp G accelerates hemostasis and speeds wound healing.
Collatamp G Safely Delivers the Appropriate Dosage
Gentamicin is released by a combination of diffusion and natural enzymatic breakdown of the collagen matrix. This provides both rapid and prolonged release, which has been mathematically modeled. The matrix itself is fully resorbable within one to seven weeks according to implant location (i.e., well-vascularized areas versus cavities).